ALHEMO
LaunchmAbBLAINJECTIONSOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ALHEMO by Novo Nordisk is concizumab-mtci is a monoclonal antibody antagonist of endogenous tissue factor pathway inhibitor (tfpi). First approved in 2025.
Drug data last refreshed 43m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALHEMO (concizumab-mtci) is a monoclonal antibody that inhibits Tissue Factor Pathway Inhibitor (TFPI) to enhance thrombin generation and clot formation in patients with Hemophilia A or B. The mechanism works independently of inhibitory antibodies to clotting factors, making it effective across the full inhibitor-status population. This represents a novel approach to hemostasis in hemophilia management.
Growth
Early-stage launch in a specialized rare disease market with moderate competitive pressure (30) suggests building commercial infrastructure and expanding market penetration opportunities.
Mechanism of Action
Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
Started May 2025
30 enrolled
Haemophilia A, Haemophilia B
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Started Aug 2024
23 enrolled
Haemophilia AHaemophilia B
Worked on ALHEMO at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.